We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA WARNS SANDOZ ABOUT ADVERTISEMENT

FDA WARNS SANDOZ ABOUT ADVERTISEMENT

June 8, 2006

The FDA has issued a warning letter to Sandoz citing violations of the Federal Food, Drug, and Cosmetic Act's (FDCA) advertising standards in relation to print ads for bupropion hydrochloride extended-release tablets (SR).

The letter, sent May 26 and posted on the FDA's website May 30, finds that Sandoz's print advertisement for SR violates the FDCA by improperly using a reminder ad for SR because the drug, which is used to treat depression, has a boxed warning, the letter says. The FDCA does not allow reminder ads, which call attention to the name of a drug product without telling what its indications are, to be used when there is a boxed warning.

The company also failed to include SR's side effects, contraindications and effectiveness data in the ad. Reminder ads are exempted from providing this data, but since a reminder ad is not allowed for SR, this additional information was necessary, the letter adds.

The FDA called on Sandoz to "immediately cease" the ad and asked for a response by June 12. Sandoz responded in a May 30 letter that the ads have not run since last October and will not be used again, Steve Eisenberg, a company spokesman said.

To view the letter, go to: http://www.fda.gov/cder/warn/2006/Bupropion-letter.pdf (http://www.fda.gov/cder/warn/2006/Bupropion-letter.pdf)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing